Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

References

• HoffmanPCMauerAMVokesEELung cancerLancet2000355920247948510841143
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• BaselgaJWhy the epidermal growth factor receptor? The rationale for cancer therapyOncologist20027Suppl 42812202782
   PubMed Web of Science ®Google Scholar
• GschwindAFischerOMUllrichAThe discovery of receptor tyrosine kinases: targets for cancer therapyNat Rev Cancer20044536137015122207
   PubMed Web of Science ®Google Scholar
• BaselgaJArteagaCLCritical update and emerging trends in epidermal growth factor receptor targeting in cancerJ Clin Oncol200523112445245915753456
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• HannaNLilenbaumRAnsariRPhase II trial of cetuximab in patients with previously treated non-small-cell lung cancerJ Clin Oncol200624335253525817114658
   PubMed Web of Science ®Google Scholar
• RobertFBlumenscheinGHerbstRSPhase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancerJ Clin Oncol200523369089909616301597
   PubMed Web of Science ®Google Scholar
• ThieneltCDBunnPAJrHannaNMulticenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancerJ Clin Oncol200523348786879316246975
   PubMed Web of Science ®Google Scholar
• BorghaeiHLangerCJMillensonMPhase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017J Thorac Oncol20083111286129218978564
   PubMed Web of Science ®Google Scholar
• BelaniCPSchreederMTSteisRGCetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 studyCancer200811392512251718816622
   PubMed Web of Science ®Google Scholar
• SocinskiMASalehMNTrentDFA randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)Ann Oncol20092061068107319188136
   PubMed Web of Science ®Google Scholar
• RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol200819236236917947225
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937396741525153119410716
   PubMed Web of Science ®Google Scholar
• O’ByrneKEberhardtWEEStörkelSUse of a continuous EGFR IHC scoring method reveals association between tumor response and EGFR expression levels for patients receiving CT + cetuximab versus CT alone in the phase III trial FLEX in advanced NSCLCJ Thorac Oncol20105Suppl 7S558S559
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrPaulusRCurranWJPhase II study of cetuximab in combination with chemoradiation in patients with stage iiia/b non-small-cell lung cancer: RTOG 0324J Clin Oncol201129172312231821555682
   PubMed Web of Science ®Google Scholar
• MateoCMorenoEAmourKLombarderoJHarrisWPerezRHumanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activityImmunotechnology19973171819154469
   PubMedGoogle Scholar
• Crombet-RamosTRakJPerezRViloria-PetitAAntiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibodyInt J Cancer2002101656757512237899
   PubMed Web of Science ®Google Scholar
• AkashiYOkamotoIIwasaTEnhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor statusBr J Cancer200898474975518253126
   PubMed Web of Science ®Google Scholar
• CrombetTOsorioMCruzTUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patientsJ Clin Oncol20042291646165415117987
   PubMed Web of Science ®Google Scholar
• RodriguezMORiveroTCdel Castillo BahiRNimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neckCancer Biol Ther20109534334920448462
   PubMed Web of Science ®Google Scholar
• ArteagaMELedonNCasacoASystemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody NimotuzumabCancer Biol Ther2007691390139517827980
   PubMed Web of Science ®Google Scholar
• BolandWKBebbGNimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicityExpert Opin Biol Ther2009991199120619624281
   PubMed Web of Science ®Google Scholar
• TalaveraAFriemannRGomez-PuertaSNimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformationCancer Res200969145851585919584289
   PubMed Web of Science ®Google Scholar
• GarridoGTikhomirovIARabasaABivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profileCancer Biol Ther201111437338221150278
   PubMed Web of Science ®Google Scholar
• Diaz MiqueliARolffJLemmMFichtnerIPerezRMonteroERadiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodiesBr J Cancer2009100695095819293809
   PubMed Web of Science ®Google Scholar
• CrombetTTorresLNeningerEPharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancerJ Immunother200326213914812616105
   PubMed Web of Science ®Google Scholar
• YouBBradeAMagalhaesJMA dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignanciesInvest New Drugs2011295996100320454832
   PubMed Web of Science ®Google Scholar
• BokuNYamazakiKYamamotoNPhase I study of nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors in Japan [abstract]J Clin Oncol200927Suppl 15se14574
   Google Scholar
• BebbGSmithCRorkeSPhase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapyCancer Chemother Pharmacol201167483784520563810
   PubMed Web of Science ®Google Scholar
• ChoiHJSohnJHLeeCGA phase I study of nimotuzumab in combination with radiotherapy in stages IIB–IV non-small cell lung cancer unsuitable for radical therapy: Korean resultsLung Cancer2011711555920451284
   PubMed Web of Science ®Google Scholar
• MaciasANeningerESantiestebanEPreliminary results of a phase II clinical trial of the anti EGFR monoclonal antibody Nimotuzumab in combination with whole brain radiation therapy in patients diagnosed with advanced non-small cell lung cancer tumors unresectable brain metastases [abstract]Proceedings of the 20th EORTC-NCI-AACR Annual MeetingOctober 21–24, 2008Geneva, Switzerland2008505
   Google Scholar
• DillmanROSeagrenSLPropertKJA randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancerN Engl J Med1990323149409452169587
   PubMed Web of Science ®Google Scholar
• SauseWKolesarPTaylorSIFinal results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology GroupChest2000117235836410669675
   PubMed Web of Science ®Google Scholar
• FuruseKFukuokaMKawaharaMPhase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancerJ Clin Oncol19991792692269910561343
   PubMed Web of Science ®Google Scholar
• CurranWScottCLangerCLongterm benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 [abstract]Proc Am Soc Clin Oncol2003222499
   Google Scholar
• YamamotoNNakagawaKNishimuraYPhase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105J Clin Oncol201028233739374520625120
   PubMed Web of Science ®Google Scholar
• TanakaKOkamotoIYamamotoNPhase 2 study of nimotuzumab in combination with concurrent chemoradiotherapy (CRT) in patients with locally advanced non-small cell lung cancer (NSCLC) [abstract]Proceedings of the European Multidisciplinary Cancer CongressSeptember 23–27, 2011Stockholm, Sweden abstract 9.044
   Google Scholar
• LynchTJPatelTDreisbachLCetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099J Clin Oncol201028691191720100966
   PubMed Web of Science ®Google Scholar
• LinHJiangJLiangXZhouXHuangRChemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysisLung Cancer2010701576220149474
   PubMed Web of Science ®Google Scholar
• MukoharaTEngelmanJAHannaNHDifferential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutationsJ Natl Cancer Inst200597161185119416106023
   PubMedGoogle Scholar
• GatzemeierUPaz-AresLRodrigues PereiraJvon PawelJRamlauRRohJMolecular and clinical biomarkers of cetuximab efficacy: data from the phase III FLEX study in non-small cell lung cancer (NSCLC) [abstract]J Thorac Oncol20094Suppl 1S324
   Google Scholar
• Khambata-FordSHarbisonCTHartLLAnalysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancerJ Clin Oncol201028691892720100958
   PubMed Web of Science ®Google Scholar
• GatzemeierUvon PawelJVynnychenkoIFirst-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 studyLancet Oncol2011121303721169060
   PubMed Web of Science ®Google Scholar